Medigene participates at upcoming conferences
Planegg/Martinsried (30.06.2021) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will participate at the following upcoming financial and scientific conferences. Medigene's management and/or scientists will be available for one-on-one meetings at these events.
CAR-TCR Summit
31 August - 2 September 2021
H.C. Wainwright 23rd Annual Global Investment Conference
13-15 September 2021
https://hcwevents.com/annualconference/
ESMO Congress
16-21 September 2021
https://www.esmo.org/meetings/esmo-congress-2021
Baader Investment Conference
20-24 September 2021
https://www.baaderinvestmentconference.com/
About Medigene
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Planegg/Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to enhance T cell activity against solid cancers in fields of high unmet medical need. Medigene's pipeline includes pre-clinical as well as clinical programs in development.
Medigene's strategy is to develop its own therapies towards clinical proof-of-concept. In addition, the Company offers selected partners the opportunity to discover and develop therapies on the basis of its proprietary technology platforms. In return for such partnerships, Medigene expects to receive upfront and milestone payments as well as research and development funding and royalties on future product sales.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene
Dr. Anna Niedl
Phone: +49 89 2000 3333 01
e-mail: [email protected]
LifeSci Advisors
Mary-Ann Chang
Phone: +44 7483 284 853
e-mail: [email protected]
In case you no longer wish to receive any information about Medigene, please inform us by e-mail ([email protected]). We will then delete your address from our distribution list.
(end)
emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg/Martinsried
country: Germany
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
e-mail: [email protected]
website: www.medigene.com
Medigene AG Stock
The community is currently still undecided about Medigene AG with 0 Buy predictions and 2 Sell predictions.
This results in a negative potential of -32.2% based on a current price of 1.48 € and a target price of 1 € for the stock.
